Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.
The U.S. Food and Drug Administration approved Mimrylo (rusfertide), developed by Takeda Pharmaceutical and Protagonist Therapeutics, as the first drug of its kind to treat polycythemia vera, a rare blood disorder that causes overproduction of red blood cells.
Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.
China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.
ADC Therapeutics shares plunged 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients, despite meeting its main goal. The safety signal represents a significant setback for the company's development program.
Allogene Therapeutics reported new data showing its allogeneic (off-the-shelf) CAR-T treatment successfully eliminated residual cancer cells in B-cell lymphoma patients, potentially offering an easier-to-administer alternative that could delay or prevent cancer recurrence.
Scientists at St. Jude Children's Research Hospital, the American Society for Hematology, and Munich Leukemia Laboratory created a data-sharing platform that unites genomics, gene expression, and clinical data for blood cancers.
